Oncoinvent ASA (OSL:ONCIN)
80.20
-0.80 (-0.99%)
Aug 4, 2026, 3:56 PM CET
Oncoinvent ASA Revenue
In the year 2025, Oncoinvent ASA had annual revenue of 28.07M NOK with 246.40% growth. Oncoinvent ASA had revenue of 16.11M in the half year ending December 31, 2025, with 4,450.56% growth.
Revenue
28.07M
Revenue Growth
+3,210.02%
P/S Ratio
12.92
Revenue / Employee
637.93K
Employees
44
Market Cap
362.75M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.07M | 19.97M | 246.40% |
| Dec 31, 2024 | 8.10M | 7.75M | 2,188.98% |
| Dec 31, 2023 | 354.00K | -5.93M | -94.37% |
| Dec 31, 2022 | 6.28M | 5.51M | 711.76% |
| Dec 31, 2021 | 774.00K | 173.00K | 28.79% |
| Dec 31, 2020 | 601.00K | -8.30M | -93.25% |
| Dec 31, 2019 | 8.90M | 6.57M | 281.16% |
| Dec 31, 2018 | 2.34M | - | - |
| Dec 31, 2017 | 0 | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ArcticZymes Technologies ASA | 128.37M |
| Arctic Bioscience AS | 42.62M |
| SoftOx Solutions AS | 16.27M |
| Aqua Bio Technology ASA | 7.53M |
| Nykode Therapeutics AS | 5.42M |
| Thor Medical ASA | 839.00K |
| Lytix Biopharma ASA | 377.00K |
| Circio Holding ASA | 123.00K |
Oncoinvent ASA News
- 2 months ago - Oncoinvent ASA Slides: Investor presentation - Filings
- 3 months ago - Oncoinvent ASA Transcript: Investor update - Transcripts
- 3 months ago - Oncoinvent ASA Slides: Investor update - Filings
- 5 months ago - Oncoinvent ASA Slides: DNB Carnegie Nordic Healthcare Conference presentation - Filings
- 5 months ago - Oncoinvent ASA Earnings Call Transcript: Q4 2025 - Transcripts
- 5 months ago - Oncoinvent ASA Quarterly report: Q4 2025 - Filings
- 5 months ago - Oncoinvent ASA Slides: Q4 2025 - Filings
- 5 months ago - Oncoinvent ASA Annual report: Q4 2025 - Filings